Summary of ssbd-repos-000372

Name
URL
DOI

Title
Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas
Description

High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecological malignancy. To date, the profiles of gene mutations and copy number alterations in HGSOC have been well characterized. However, the patterns of epigenetic alterations and transcription factor dysregulation in HGSOC have not yet been fully elucidated. In this study, we performed integrative omics analyses of a series of stepwise HGSOC model cells originating from human fallopian tube secretory epithelial cells (HFTSECs) to investigate early epigenetic alterations in HGSOC tumorigenesis. Assay for transposase-accessible chromatin using sequencing (ATAC-seq), chromatin immunoprecipitation sequencing (ChIP-seq), and RNA sequencing (RNA-seq) methods were used to analyze HGSOC samples. Additionally, protein expression changes in target genes were confirmed using normal HFTSECs, serous tubal intraepithelial carcinomas (STICs), and HGSOC tissues. Transcription factor motif analysis revealed that the DNA-binding activity of the AP-1 complex and GATA family proteins was dysregulated during early tumorigenesis. The protein expression levels of JUN and FOSL2 were increased, and those of GATA6 and DAB2 were decreased in STIC lesions, which were associated with epithelial- mesenchymal transition (EMT) and proteasome downregulation. The genomic region around the FRA16D site, containing a cadherin cluster region, was epigenetically suppressed by oncogenic signaling. Proteasome inhibition caused the upregulation of chemokine genes, which may facilitate immune evasion during HGSOC tumorigenesis. Importantly, MEK inhibitor treatment reversed these oncogenic alterations, indicating its clinical effectiveness in a subgroup of patients with HGSOC. This result suggests
that MEK inhibitor therapy may be an effective treatment option for chemotherapy-resistant HGSOC.

Submited Date
2024-07-29
Release Date
2024-11-21
Updated Date
2024-09-13
License
Funding information
-
File formats
TIF
Data size
47.4 MB

Organism
Homo sapiens
Strain
-
Cell Line
-
Genes
-
Proteins
-

GO Molecular Function (MF)
-
GO Biological Process (BP)
-
GO Cellular Component (CC)
-
Study Type
-
Imaging Methods
-

Method Summary

See details in Machino, et. al. (2023) Exp Mol Med.

Related paper(s)

Hidenori Machino, Ai Dozen, Mariko Konaka, Masaaki Komatsu, Kohei Nakamura, Noriko Ikawa, Kanto Shozu, Ken Asada, Syuzo Kaneko, Hiroshi Yoshida, Tomoyasu Kato, Kentaro Nakayama, Vassiliki Saloura, Satoru Kyo, Ryuji Hamamoto (2023) Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas., Experimental & molecular medicine

Published in 2023 Oct 2 (Electronic publication in Oct. 2, 2023, midnight )

(Abstract) High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecological malignancy. To date, the profiles of gene mutations and copy number alterations in HGSOC have been well characterized. However, the patterns of epigenetic alterations and transcription factor dysregulation in HGSOC have not yet been fully elucidated. In this study, we performed integrative omics analyses of a series of stepwise HGSOC model cells originating from human fallopian tube secretory epithelial cells (HFTSECs) to investigate early epigenetic alterations in HGSOC tumorigenesis. Assay for transposase-accessible chromatin using sequencing (ATAC-seq), chromatin immunoprecipitation sequencing (ChIP-seq), and RNA sequencing (RNA-seq) methods were used to analyze HGSOC samples. Additionally, protein expression changes in target genes were confirmed using normal HFTSECs, serous tubal intraepithelial carcinomas (STICs), and HGSOC tissues. Transcription factor motif analysis revealed that the DNA-binding activity of the AP-1 complex and GATA family proteins was dysregulated during early tumorigenesis. The protein expression levels of JUN and FOSL2 were increased, and those of GATA6 and DAB2 were decreased in STIC lesions, which were associated with epithelial-mesenchymal transition (EMT) and proteasome downregulation. The genomic region around the FRA16D site, containing a cadherin cluster region, was epigenetically suppressed by oncogenic signaling. Proteasome inhibition caused the upregulation of chemokine genes, which may facilitate immune evasion during HGSOC tumorigenesis. Importantly, MEK inhibitor treatment reversed these oncogenic alterations, indicating its clinical effectiveness in a subgroup of patients with HGSOC. This result suggests that MEK inhibitor therapy may be an effective treatment option for chemotherapy-resistant HGSOC.

Contact(s)
Hidenori Machino, Ryuji Hamamoto
Organization(s)
RIKEN Center for Advanced Intelligence Project , Cancer Translational Research Team
Image Data Contributors
Quantitative Data Contributors

Download files
Download zipped files